GTC Biotherapeutics (fka GTCB)

[MTB]

Hi Dak,

I think the subset analysis of Kybersept and Dr. Ruf's findings DO jib.

Again, the key take away for me from that study is that 1) thrombin is the key mediator of sepsis in this model, and 2) that blocking thrombin (in this case with hirudin) reverses this process. Overall, (though not without reservation), this is a significant chunk of (very well conducted) experimental evidence that suggests ATIII WILL have good effect in sepsis.

Any strong experimental evidence that ATIII will have good effect in AD indications (DIC) are a step towards $10+/share GTCB, and aren't to be taken lightly. These data will NOT go overlooked by potental partners.

Ruf's findings of lymphatic etiology for inflammation in sepsis and his finding of good effect by hirudin (in blocking thrombin) no not contradict our expectation that ATIII will have good effect. His tangential comments on the likelihood and mechanism of hirudin maybe being more present in the lymphatics than ATIII are simply conjecture -- and in my mind aren't worth arguing with or against. It would be easier simply to do an experiment!

Cheers,
MTB